Advertisement

Journal of Gastrointestinal Cancer

, Volume 50, Issue 4, pp 983–990 | Cite as

A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?

  • Anil Kumar Singh Rana
  • Nitin AgarwalEmail author
  • Sushant Dutta
  • Manoj Kumar Dokania
  • Himank Goyal
Case Report
  • 35 Downloads

Introduction

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged as feasible treatment modalities for peritoneal dissemination (pseudomyxoma peritonei—PMP) in selected malignancies of the ovaries, appendix, colorectum, stomach, and even urinary bladder [1, 2, 3]. The time period after 2010 has seen a noticeable boost in the number of centers adopting this technique [3]. It has been shown that removing all macroscopic tumor tissue from the peritoneal surface (residual < 2.5 mm) facilitates destruction of the residual cells by local chemotherapy, heated to 40–45 °C for maximum penetration. This approach has shown better survival and less complication rates than systemic chemotherapy administered pre-or postoperatively in the same subset of patients. Better results have been demonstrated in certain pathological subtypes of PMP like metastatic colorectal carcinoma and disseminated peritoneal adenomucinosis (DPAM) [4, 5].

Since the procedure is...

Abbreviations

HIPEC

Hyperthermic intraperitoneal chemotherapy

CRS

Cytoreductive surgery

PCI

Peritoneal cancer index

CC

Completeness of cytoreduction

DPAM

Disseminated peritoneal adenomucinosis

PMP

Pseudomyxoma peritonei

Notes

Authors’ Contributions

Rana AKS: idea, clinical contribution, editing

Agarwal N: idea, clinical contribution, writing of manuscript, and editing

Dutta S: writing of manuscript and editing

Dokania MK: writing of manuscript and editing

Goyal H: writing of manuscript and editing.

Compliance with Ethical Standards

Ethics Approval and Consent to Participate

Informed consent was taken from the patient; the study is case report which conforms to the standards of the institutional ethics committee.

Consent for Publication

Informed consent was taken from the patient.

Availability of Data and Material

Not applicable.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45(8):527–75.  https://doi.org/10.1067/j.cpsurg.2008.04.003. ReviewCrossRefPubMedGoogle Scholar
  2. 2.
    Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57.  https://doi.org/10.3978/j.issn.2078-6891.2015.111. ReviewCrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, et al. Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol. 2016;8(1):67–82.  https://doi.org/10.4251/wjgo.v8.i1.67.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sugarbaker PH. The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasms. Eur J Surg Oncol. 2006;32:644–7.CrossRefGoogle Scholar
  5. 5.
    Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456–62.CrossRefGoogle Scholar
  6. 6.
    Bhatt A, Mehta S, Seshadri RA, Sethna K, Zaveri S, Rajan F, et al. The initial Indian experience with cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7(2):160–5.  https://doi.org/10.1007/s13193-016-0500-x. Epub 2016 Feb 2CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Padmanabhan N, Kumar BR, Pookunju AP, Srinivasan A, Mahajan V. Preliminary experience and morbidity analysis of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) from a tertiary cancer center in India. J Clin Diagn Res. 2015;9(6):XC09–13.  https://doi.org/10.7860/JCDR/2015/14216.6075.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dharmadhikari N, Shah R, Jagannath P. Initial experience with hyperthermic intra peritoneal chemotherapy and cytoreductive surgery. Indian J Cancer. 2014;51(2):189–92.  https://doi.org/10.4103/0019-509X.138304.CrossRefPubMedGoogle Scholar
  9. 9.
    Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133–9.  https://doi.org/10.1016/j.jss.2012.01.015.CrossRefPubMedGoogle Scholar
  10. 10.
    Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16(8):2181–7.  https://doi.org/10.1245/s10434-009-0523-4.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hinkle NM, MacDonald J, Sharpe JP, Dickson P, Deneve J, Munene G. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program. Am J Surg. 2016;212:413–8.  https://doi.org/10.1016/j.amjsurg.2016.01.022.CrossRefPubMedGoogle Scholar
  12. 12.
    Squires MH III, Staley CA, Knechtle W, Winer JH, Russell MC, Perez S, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Ann Surg Oncol. 2015;22(5):1739–45.  https://doi.org/10.1245/s10434-014-4025-7.CrossRefPubMedGoogle Scholar
  13. 13.
    Cravioto-Villanueva A, Cavazos M, Luna-Perez P, Martinez-Gomez H, Ramirez ML, Solorzano J, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. Surg Today. 2016;46(8):979–84.  https://doi.org/10.1007/s00595-016-1335-3.CrossRefPubMedGoogle Scholar
  14. 14.
    Ortega-Deballon P, Facy O, Magnin G, Piard F, Chauffert B, Rat P. Using a heating cable within the abdomen to make hyperthermic intraperitoneal chemotherapy easier: feasibility and safety study in a pig model. Eur J Surg Oncol. 2010;36(3):324–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Surgery, Renal Transplant UnitPostgraduate Institute of Medical Education and Research (PGIMER) and Dr. Ram Manohar Lohia Hospital (RMLH)DelhiIndia

Personalised recommendations